Nukleäre Rezeptoren als Regulatoren der Gewebeantwort und neue Therapieansätze bei fibrotischen Erkrankungen

• Antragsteller: Professor Dr. Jörg Hans Wilhelm Distler
• Fachliche Zuordnung: Rheumatologie
• Förderung: Förderung von 2014 bis 2021
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 258918299

• Erstellungsjahr: 2020

Zusammenfassung der Projektergebnisse

Keine Zusammenfassung vorhanden

Projektbezogene Publikationen (Auswahl)

• Hippocampal structure and function are maintained despite severe innate peripheral inflammation. Brain, Behavior, and Immunity, Vol. 49. 2015, pp. 156-170.
  Süß P., Kalinichenko L., Baum W., Reichel M., Kornhuber J., Loskarn S., Ettle B., Distler J.H., Schett G., Winkler J., Müller C.P., Schlachetzki J.C.
  (Siehe online unter https://doi.org/10.1016/j.bbi.2015.05.011)
• Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clinical Chemistry and Laboratory Medicine (CCLM), Band 53. 2015, Heft 11, S. 1799-1805.
  Legány N., Toldi G., Distler J.H., Beyer C., Szalay B., Kovács L., Vásárhelyi B., Balog A.
  (Siehe online unter https://doi.org/10.1515/cclm-2015-0079)
• Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, Vol. 75. 2016, Issue 11, pp. 2037-2044.
  Lin N.Y., Distler A., Beyer C., Philipi-Schöbinger A., Breda S., Dees C., Stock M., Tomcik M., Niemeier A., Dell'Accio F., Gelse K., Mattson M.P., Schett G., Distler J.H.
  (Siehe online unter https://doi.org/10.1136/annrheumdis-2015-208420)
• N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. International Journal of Cardiology, Vol. 223. 2016, pp. 385-389.
  Allanore Y-, Komocsi A-, Vettori S-, Hachulla E-, Hunzelmann N-, Distler J-, Avouac J-, Gobeaux C-, Launay D-, Czirjak L-, Kahan A-, Meune C.
  (Siehe online unter https://doi.org/10.1016/j.ijcard.2016.08.246)
• Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clinical and Experimental Rheumatology, Vol. 35. 2017, Suppl. 106, pp. S75-S81.
  Distler O., Brown K.K., Distler J.H.W., Assassi S., Maher T.M., Cottin V, Varga J., Coeck C., Gahlemann M., Sauter W., Schmidt H., Highland K.B., SENSCIS™ trial investigators
  
• Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Experimental Dermatology, Vol.26. 2017, Issue 1, pp. 73-81.
  Dosoki H., Stegemann A., Taha M., Schnittler H., Luger T.A., Schröder K., Distler J.H., Kerkhoff C., Böhm M.
  (Siehe online unter https://doi.org/10.1111/exd.13180)
• Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, Vol. 9. 2018: 989.
  Biermann M.H.C., Boeltz S., Pieterse E., Knopf J., Rech J., Bilyy R., van der Vlag J., Tincani A., Distler J.H.W., Krönke G., Schett G.A., Herrmann M., Muñoz L.E.
  (Siehe online unter https://doi.org/10.3389/fimmu.2018.00989)
• NR4A1 regulates motility of osteoclast precursors and serves as target for the modulation of systemic bone turnover. Journal of Bone and Mineral Research, Vol. 33. 2018, Issue 11 pp. 2035-2047.
  Scholtysek C., Ipseiz N., Böhm C., Krishnacoumar B., Stenzel M., Czerwinski T., Weidner D., Klej A., Stoll C., Distler J., et al.
  (Siehe online unter https://doi.org/10.1002/jbmr.3533)
• Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Journal of Rheumatology, Vol. 45. 2018, Issue 3, pp. 405-410.
  Hsu V.M., Denton C.P., Domsic R.T., Furst D.E., Rischmueller M., Stanislav M., Steen V.D., Distler J.H.W., Korish S., Cooper A., Choi S., Schafer P.H., Horan G., Hough D.R.
  (Siehe online unter https://doi.org/10.3899/jrheum.161040)
• GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, Vol. 10. 2019, Issue 1, Article number: 4955.
  López-Isac E., Acosta-Herrera M., Distler J.H.W., Martin J., et al.
  (Siehe online unter https://doi.org/10.1038/s41467-019-12760-y)
• Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Annals of the Rheumatic Diseases, Vol. 78. 2019, Issue 12, pp. 1686-1692.
  Matei A.E., Chen C.W., Kiesewetter L., Györfi A.H., Li Y.N., Distler J.H.W., et al.
  (Siehe online unter https://doi.org/10.1136/annrheumdis-2019-216108)